Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 All of the involved markers in BC susceptibility among the Iranian patients

From: Genetic and molecular biology of breast cancer among Iranian patients

Study (et al.) Year Gene Type Population Results
Danesh [17] 2018 miR-218-2, miR-301b Sporadic 288 Controls
266 Patients
Polymorphism was correlated with BC risk
Heydari [19] 2018 mir-140-3p Sporadic 40 Controls
40 Patients
Over expression
Parchami Barjui [20] 2017 miR-502 Sporadic 231 Controls
240 Patients
Polymorphism was correlated with BC risk
Omrani [21] 2014 hsa-miR-499 Sporadic 203 Controls
236 Patients
Polymorphism was correlated with BC risk
Hashemi [23] 2016 mir-608 Sporadic 192 Controls
160 Patients
Polymorphism was correlated with BC risk
Savad [26] 2012 miR-342 Sporadic 77 N/Ta Over expression in ER/PR positive tumors
Mansoori [28] 2016 miR34a, let-7a Sporadic 45 N/T Under expression
Saberi [29] 2016 miR-328 Sporadic 28 N/T Over expression
Damavandi [30] 2016 miR-132, miR-212, and miR-22 Sporadic 36 N/T Correlation with grade and stage
Nejati-Azar [32] 2018 miR-196a Sporadic 200 Controls
200 Patients
Polymorphism was correlated with BC risk
Sarrafzadeh [35] 2017 CCAT2 Familial/
Sporadicb
48 N/T Correlation with stage an lymph node metastasis
Hassanzarei [37] 2017 HOTAIR Sporadic 231 Controls
220 Patients
Polymorphism was correlated with BC risk
Miri [42] 2012 eRF3a/GSPT1 Familial/
Sporadic
250 Controls
250 Patients
Polymorphism was correlated with BC risk
Hosseini [45] 2011 MTHFR Sporadic 306 Controls
294 Patients
Polymorphism was correlated with BC risk
Rezaei [46] 2017 MTHFR Familial/
Sporadic
84 Patients Polymorphism was correlated with BC risk
Jahangiri [48] 2018 DNMT1, DNMT3A, and DNMT3B Sporadic 72 Patients Correlation with grade
Eftekhar [49] 2014 DNMT3B Sporadic 138 Controls
100 Patients
Polymorphism was correlated with BC risk
Hashemi [51] 2012 CASP8 Sporadic 203 Controls
236 Patients
Polymorphism was correlated with BC risk
Aghababazadeh [52] 2017 CASP8 Familial/
Sporadic
27 N/T Under expression
Eskandari-Nasab [54] 2015 TP53 Sporadic 203 Controls
236 Patients
Polymorphism was correlated with BC risk
Payandeh [55] 2016 P53 Sporadic 231 Patients Correlation with grade and lymph node metastasis
Rostamizadeh [58] 2013 BCL-2 Sporadic 40 Patients Correlation with grade and survival
Golmohammadi [61] 2016 PTEN Sporadic 100 Patients Correlation with stage and survival
Sadeq [62] 2011 PTEN Sporadic 20 Controls
57 Patients
Hypermethylation was correlated with stage and lymph node metastasis
Yari [63] 2016 PTEN Familial/
Sporadic
50 Controls
103 Patients
Methylation
Ghaffari [64] 2016 BIRC5 Sporadic 40 Patients Correlation with age
Vallian [70] 2009 p16INK4A Sporadic 70 Controls
70 Patients
Methylation was correlated with stage
Salimi [72] 2012 ATM and cyclinD1 Sporadic 119 Patients ATM under expression and cyclinD1 over expression
Mehdipour [73] 2011 ATM Sporadic 248 Controls
129 Patients
Polymorphism was correlated with BC risk
Amininia [75] 2014 CCNE1 Sporadic 225 Controls
266 Patients
Polymorphism was correlated with BC risk
Hajikhan Mirzaei [78] 2012 DBC2 Sporadic 50 Patients Methylation
Golmohammadi [79] 2017 AURKA Sporadic 100 Controls
100 Patients
Polymorphism was correlated with BC risk
Mojgan [80] 2012 ERCC1 Sporadic 126 Controls
300 Patients
Polymorphism was correlated with BC risk
Jalali [83] 2016 XRCC1 Sporadic 200 Controls
100 Patients
Polymorphism was correlated with BC risk
Rezaei [86] 2016 FEN1 Sporadic 225 Controls
266 Patients
Mutation
Madjd [88] 2014 EMSY Familial/
Sporadic
116 Patients Correlation with tumor size and lymph node metastasis
Hallajian [91] 2017 ATM, RAD51, and BRCA1 Sporadic 50 Patients Under expression
Darbeheshti [94] 2018 BRCA1 Sporadic 53 Patients Correlation with grade and lymph node metastasis
Madjd [95] 2011 BRCA1 Familial/
Sporadic
156 Patients Correlation with grade
Rezaei [96] 2015 APOBEC3 Sporadic 217 Controls
262 Patients
Mutation
Abbasi [98] 2017 FANCA Familial/
Sporadic
295 Controls
304 Patients
Mutation
Hashemi [102] 2014 hTERT Sporadic 225 Controls
266 Patients
Polymorphism was correlated with BC risk
Haghi [108] 2015 HLA-G Sporadic 255 Controls
227 Patients
Polymorphism was correlated with BC risk
Mahmoodi [109] 2012 HLA-II Sporadic 80 Controls
100 Patients
Polymorphism was correlated with BC risk
Ghaderi [110] 2001 HLADRB1 Sporadic 36 Controls
36 Patients
Polymorphism was correlated with BC risk
Faghih [113] 2009 IL13 Sporadic 195 Controls
305 Patients
Polymorphism was correlated with BC risk
Khodadadi [119] 2014 IL-27 and IL-23 Sporadic 50 Controls
50 Patients
Over expression
Vahedi [120] 2018 CCR7 Sporadic 70 N/T Correlation with stage, grade, and lymph node metastasis
Jafarzadeh [123] 2015 CCL22 Sporadic 100 Controls
100 Patients
Correlation with stage
Dayer [124] 2018 CXCR4 Sporadic 36 N/T Over expression in HER2 positive tumors
Jaberipour [127] 2010 FOXP3 and CTLA-4 Sporadic 40 Controls
55 Patients
Correlation with stage and grade
Hamidinia [128] 2013 FOXP3 and OX40 Sporadic 40 Controls
40 Patients
Correlation with stage
Rostami [134] 2015 Leptin Sporadic 171 Controls
203 Patients
Polymorphism was correlated with BC risk
Mohammadzadeh [136] 2015 Leptin Sporadic 100 Controls
100 Patients
Polymorphism was correlated with BC risk
Pornour [140] 2014 DRD2, DRD4 Sporadic 30 Controls
30 Patients
Over expression
Amani [141] 2014 TGFβ1 Sporadic 110 Controls
110 Patients
Polymorphism was correlated with BC risk
Parvizi [142] 2016 TGF-β Sporadic 100 Controls
100 Patients
Polymorphism was correlated with BC risk
Tabatabaeian [143] 2013 HER-2 Familial/sporadic 15 Controls
80 Patients
Over expression
Panahi [144] 2013 HER-2 Familial 299 Patients Correlation with ER/PR
Amirifard [145] 2016 HER-2 Familial/sporadic 130 Patients Correlation with stage and age
Salimi [146] 2016 ERBB4 Familial/sporadic 192 Controls
172 Patients
Polymorphism was correlated with BC risk
Mansouri Bidkani [147] 2018 ERBB4 Familial/sporadic 148 Controls
172 Patients
Polymorphism was correlated with BC risk
Bagheri [148] 2016 ERBB4 Sporadic 146 Controls
146 Patients
Polymorphism was correlated with BC risk
Eskandari-Nasab [152] 2012 NGX6 Sporadic 203 Controls
236 Patients
Under expression
Seifi-Alan [154] 2018 NRP1 Sporadic 48 N/T Correlation with stage, grade, and lymph node metastasis
Javadi [156] 2012 IGF-1 Familial/sporadic 224 Controls
215 Patients
Mutation
Azizi Tabesh [158] 2017 PIK3CA Sporadic 80 Patients Mutation
Sanaei [159] 2017 KRAS Sporadic 204 Controls
244 Patients
Polymorphism was correlated with BC risk
Nazouri [160] 2017 SPHK1 Sporadic 120 Patients Correlation with BMI
Heshmatpour [164] 2014 PIK3CA Sporadic 200 Controls
200 Patients
Polymorphism was correlated with BC risk
Ghalaei [165] 2018 APPL2 and OCC1 Sporadic 30 N/T APPL2 under expression and OCC1 over expression
Karami-Tehrani [166] 2016 RIP1K and RIP3K Sporadic 20 Normal
45 Tumor
Correlation with grade
Nikseresht [168] 2010 UBE2Q2 Sporadic 21 N/T Over expression
Hashemi [170] 2012 GSTM1, GSTT1, GSTP1 Sporadic 152 CONTROLS
134 PATIENTS
Polymorphism was correlated with BC risk
Sharif [171] 2017 GSTO1, GSTO2 Sporadic 150 Controls
153 Patients
Polymorphism was correlated with BC risk
Saadatian [173] 2014 CYP1A1 Sporadic 100 Controls
100 Patients
Polymorphism was correlated with BC risk
Saghafi [174] 2018 CYP2D6 Familial/
Sporadic
84 Patients Polymorphism was correlated with BC risk
Yazdi [179] 2015 CYP2D6 Sporadic 101 Patients Polymorphism was correlated with BC risk
Homaei-Shandiz [184] 2016 HSP27 Sporadic 65 Controls
97 Patients
High levels of serum anti Hsp27
Ghafouri [187] 2016 ABCG2 Sporadic 200 Controls
100 Patients
Polymorphism was correlated with BC risk
Estiar [189] 2017 CEACAM19 Sporadic 75 Patients Over expression
Moazzezy [192] 2014 CA15-3 and CEA Sporadic 30 Controls
30 Patients
Over expression
Mansouri [193] 2016 MUC1 Sporadic 50 Patients Over expression
Zarei [196] 2017 CDH1 Sporadic 200 Controls
100 Patients
Polymorphism was correlated with BC risk
Esmaeili [198] 2018 CD44 Familial/
Sporadic
175 Controls
175 Patients
Polymorphism was correlated with BC risk
Sadeghi [202] 2017 EpCAM Sporadic 122 Patients Correlation with grade
Taghizadeh-Kermani [204] 2014 CD10 Sporadic 150 Patients Correlation with grade, lymph node metastasis, and tumor size
Fard [207] 2018 CAV-1 Sporadic 203 Controls
203 Patients
Polymorphism was correlated with BC risk
Mobasheri [208] 2016 SYCP3 Sporadic 47 Patients Over expression
Malek-Hosseini [209] 2017 SDC1 Familial/
Sporadic
30 Controls
61 Patients
Correlation with tumor size
Karami-Tehrani [213] 2012 PDE5 and PDE9 Sporadic 70 N/T Correlation with stage, grade, and lymph node metastasis
Karami-Tehrani [215] 2012 PKG Sporadic 70 N/T Under expression
Paryan [218] 2016 NOTCH1 Sporadic 20 N/T Correlation with tumor type
Taghavi [220] 2016 WISP1 Familial/
Sporadic
15 Controls
85 Patients
Correlation with age and tumor size
Madjd [224] 2012 ALDH1 Familial/
Sporadic
127 Patients Correlation with BRCA1
Jahangiri [229] 2018 PAX2 Sporadic 72 Patients Correlation with survival
Estiar [233] 2017 NDRG3 Sporadic 6 Normal
88 Tumor
Correlation with survival
Hosseini [234] 2014 ERα Sporadic 10 Normal
19 Tumor
Over expression
Abbasi [235] 2013 ERα Familial/
Sporadic
147 Controls
150 Patients
mutation
Farzaneh [236] 2016 CYP19 Sporadic 135 Controls
134 Patients
Polymorphism was correlated with BC risk
Kamali-Sarvestani [241] 2005 TNF-α Sporadic 160 Patients Polymorphism was correlated with BC risk
Vakil Monfared [245] 2018 TNFSF4 Sporadic 126 Controls
123 Patients
Polymorphism was correlated with BC risk
Colagar [250] 2015 VDR Sporadic 127 Controls
134 Patients
Microsatellite
Zhalehjoo [255] 2017 CYP24A1 and CYP27B1 Sporadic 30 N/T Correlation with stage and age
Shahabi [256] 2018 VDR Familial/
Sporadic
214 Controls
203 Patients
Polymorphism was correlated with BC risk
Shahbazi [257] 2013 VDR Sporadic 156 Controls
140 Patients
Polymorphism was correlated with BC risk
Ebrahimi [260] 2017 CYP17 Familial/
Sporadic
205 Patients Polymorphism was correlated with BC risk
Esmaeili [263] 2015 AKAP3 Sporadic 162 N/T Correlation with stage and tumor size
Nourashrafeddin [266] 2015 WBP2NL Sporadic 30 Normal
50 Tumor
Over expression
Rastgoosalami [267] 2016 MAGE-1 Sporadic 113 Patients Correlation with lymph node metastasis and tumor size
Dianatpour [268] 2012 TSGA10 Sporadic 50 Patients Expression
Kazemi-Oula [272] 2015 ODF4 and RHOXF2 Familial/Sporadic 40 N/T Over expression
Arezi [278] 2018 ND4 Sporadic 28 Normal
60 Tumor
Mutation
Ghaffarpour [282] 2014 ATPase6 Sporadic 49 Patients Mutation
  1. aTumor tissues and normal margins
  2. bBoth of familial and sporadic patients among cases